Related Experiment Videos
Antineoplastic agents. Drug interactions of clinical significance
E van Meerten1, J Verweij, J H Schellens
1Department of Medical Oncology, Rotterdam Cancer Institute, The Netherlands.
Abstract:
With the use of numerous drugs in the treatment of cancer, the potential for drug interactions is considerable. Because of the limited therapeutic indices of anticancer drugs, one should be aware that even small alterations in pharmacokinetics or pharmacodynamics may result in serious adverse effects. Pharmacokinetic drug interactions may alter absorption, bioavailability, distribution, metabolism and elimination patterns. For example, allopurinol inhibits the enzyme xanthine oxidase, thereby blocking the first-pass metabolism of mercaptopurine. Due to this drug interaction, plasma concentrations of mercaptopurine can increase up to 5-fold. Pharmacodynamic drug interactions are characterised by a similar or opposing pharmacological effect of both drugs upon the same biological system. For example, cotrimoxazole (trimethoprim-sulfamethoxazole) inhibits folic acid metabolism through direct binding to dihydrofolate reductase, an enzyme which is also inhibited by methotrexate. More pharmacological investigations are needed to understand the mechanisms and clinical implications of drug interactions with antineoplastic agents.
Insights
Cancer drug interactions are significant due to narrow therapeutic indices. Understanding pharmacokinetic and pharmacodynamic changes is crucial for managing adverse effects of anticancer agents.
Area of Science:
- Oncology
- Pharmacology
- Drug Interactions
Background:
- Anticancer drug therapy involves multiple agents, increasing the risk of significant drug interactions.
- Anticancer drugs possess narrow therapeutic indices, making them susceptible to adverse events from pharmacokinetic or pharmacodynamic alterations.
Purpose of the Study:
- To highlight the potential for drug interactions in cancer treatment.
- To explain the mechanisms of pharmacokinetic and pharmacodynamic drug interactions involving anticancer agents.
Main Methods:
- Review of known drug interactions with antineoplastic agents.
- Explanation of pharmacokinetic alterations (absorption, distribution, metabolism, elimination).
- Explanation of pharmacodynamic interactions (opposing or similar pharmacological effects).
Main Results:
- Pharmacokinetic interactions can alter drug levels; e.g., allopurinol inhibiting mercaptopurine metabolism, increasing plasma concentrations up to 5-fold.
- Pharmacodynamic interactions involve drugs affecting the same biological pathways; e.g., cotrimoxazole and methotrexate both inhibiting dihydrofolate reductase.
Conclusions:
- Drug interactions pose considerable risks in cancer treatment due to narrow therapeutic indices.
- Further research is essential to elucidate the mechanisms and clinical significance of drug interactions with anticancer therapies.